SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis

Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Shuang, Yan, Yuanliang, Xu, Zhijie, Zeng, Shuangshuang, Qian, Long, Huo, Lei, Li, Xuejun, Sun, Lunquan, Gong, Zhicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758607/
https://www.ncbi.nlm.nih.gov/pubmed/29354058
http://dx.doi.org/10.3389/fphar.2017.00960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758607/
https://www.ncbi.nlm.nih.gov/pubmed/29354058
http://dx.doi.org/10.3389/fphar.2017.00960

Ejemplares similares